Companies investing in bronchitis treatment market are interested in studying the etiology of bronchitis. Key viruses are Influenza type A and B, while key bacterial agents are Streptococcus, Mycoplasma pneumonia, and Staphylococcus. There are several risk factors when population has high disposition to develop chronic bronchitis, particularly in regions where they are exposed to high environmental pollutants. The prevalence of bronchitis is high the general population. In chronic obstructive pulmonary disease (COPD) patients, the prevalence estimates can be as high as 54%. The high burden has been highlighted as a key driver for the evolution of the bronchitis treatment market.
Other key risk factors comprise tobacco smoking, increasing age, socioeconomic status, and occupational exposure. Both pharmacological and non-pharmacological interventions have gathered considerable attention among players in the bronchitis treatment market.
Key types comprise anti-inflammatory drugs, bronchodilators, and mucolytics.
A growing number of epidemiological studies has helped shed light on pharmacological interventions, spurring research on the above segments. The growing morbidity and mortality of acute and chronic bronchitis—the two types--is a key factor driving the bronchitis market.
The bronchitis market stood at US$ 3,432.62 million in 2017 and is projected to rise at CAGR of 3.6% from 2018 to 2026.
The report segments the bronchitis treatment market on the basis of region, type, drug class, and distribution channel.
Among the two types, chronic bronchitis holds the leading share of the global market throughout the forecast period. The rise in the opportunities in this segment is the high morbidity and mortality rate. However, rate of developments in prognosis still seems tepid. Coordinated efforts made by all healthcare teams to improve the outcomes of pharmacological treatment for chronic is a key trend driving prospects in the bronchitis treatment market. Further, clinicians recommend making changes in lifestyle in reducing the morbidity of chronic bronchitis.
On the other hand, acute bronchitis is also garnering attention among drug makers and medical device manufacturers. The segment is expected to keep contributing significant revenues in coming years. In developed countries, given the high incidence, an array of studies have been done to understand the risk factors. These studies shed light on expected avenues in the bronchitis treatment market.
Over the years, nonpharmacological interventions have risen in popularity. The various drugs classes are antibiotics, bronchodilators, mucolytics, and, anti-inflammatory drugs. Of these, bronchodilators have been frequently recommended for the treatment of symptomatic COPD.
Advent of novel LAMA/LABA fixed dose combination inhalers has helped in preventing the exacerbations in COPD patients. Thus, long-acting bronchodilators have attracted research targeted toward improving the mechanism. Growing number of clinical trials has helped develop long-acting bronchodilators. The findings of these studies have paved way to guidelines for reducing COPD exacerbations, thus unlocking new prospects for players in the bronchitis treatment market. Introduction of new drug regimens in COPD treatment options has expanded the horizon for stakeholders in the market. This has also led to the approval of novel LAMA/LABA fixed combinations, opening new doors to opportunities for market players.
The key regional markets analysed in the study comprise North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Of these, North America and Europe accounted for the major share of the global bronchitis treatment market in 2017. These regional markets have been fuelled by incessant research in bronchitis therapeutics to reduce the morbidity of the disease.
On the other hand, Asia Pacific is expected to be expand at remarkably high CAGR during 2018 – 2026. Several economies are witnessing marked progress in healthcare infrastructures to meet the demand for rising various patient populations. In particular, a robust impetus to the growth of the Asia Pacific bronchitis market comes from growing demand from elderly populations. In the cohort, smoking has been a key risk factor, in the light of other respiratory problems they may be facing. Further, the regional market has seen new avenues for growth due to extensive research and development done to reduce the morbidity of chronic bronchitis due to pollutants. High presence of pollutants in numerous developing economies in Asia has bolstered these research.
Growing awareness of COPD in general population in developing economies is also a favorable trend in the expansion of potential opportunities in the bronchitis treatment market. On the other hand, there has been widespread efforts by governments in several of these nations to make public aware of the risk factors associated with cigarette smoking. Pharmaceutical companies have in recent years have come out with new non-pharmacological interventions, and the electronic media has been promoting the effectiveness of such treatments.
Asia Pacific is thus has large latent opportunities for developers of bronchodilators. The regional market is expected to clock CAGR of 4.0% from 2018 to 2026.
Companies extensively profiled in the report on the bronchitis treatment market are Boehringer Ingelheim International GmbH., Sanofi Aventis, Melinta Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Novartis AG, and AstraZeneca.
The global bronchitis treatment market was worth US$ 3,432.62 Mn and is projected to reach a value of US$ 4,719.02 Mn by the end of 2026
Bronchitis treatment market is anticipated to grow at a CAGR of 3.6% during the forecast period
North America accounted for a major share of the global bronchitis treatment market
The global bronchitis treatment market is anticipated to be driven by an increase in mortality and morbidity of bronchitis during the forecast period
Key players in the global bronchitis treatment market include AstraZeneca, Novartis AG, GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Melinta Therapeutics, Sanofi Aventis, and Boehringer Ingelheim International GmbH
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Bronchitis Treatment Market: Market Snapshot
4. Market Overview
4.1. Global Bronchitis Treatment Market: Type Overview
4.2. Global Bronchitis Treatment Market: Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Bronchitis Treatment Market Revenue Projections, 2016–2026
4.5. Porter’s Five Forces Analysis
4.6. Global Bronchitis Treatment Market Outlook
5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Market Trends
5.3. Disease Epidemiology
6. Global Bronchitis Treatment Market Analysis, by Type
6.1. Key Findings
6.2. Introduction
6.3. Global Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Type
6.4. Global Bronchitis Treatment Market Value Forecast, by Type
6.4.1. Acute Bronchitis
6.4.2. Chronic Bronchitis
6.5. Global Bronchitis Treatment Market Analysis, by Type
7. Global Bronchitis Treatment Market Analysis and Forecast, by Drug Class
7.1. Key Findings
7.2. Introduction
7.3. Global Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Drug Class
7.4. Global Bronchitis Treatment Market Value Forecast, by Drug Class
7.4.1. Antibiotics
7.4.2. Anti-inflammatory Drugs
7.4.3. Bronchodilators
7.4.4. Mucolytics
7.5. Global Bronchitis Treatment Market Analysis, by Drug Class
8. Global Bronchitis Treatment Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Global Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
8.4. Global Bronchitis Treatment Market Value Forecast, by Distribution Channel
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Online Pharmacies
8.5. Global Bronchitis Treatment Market Analysis, by Distribution Channel
9. Global Bronchitis Treatment Market Analysis, by Region
9.1. Global Bronchitis Treatment Market Scenario, by Country
9.2. Global Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Region
9.3. Global Bronchitis Treatment Market Value Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America Bronchitis Treatment Market Analysis
10.1. Key Findings
10.2. North America Bronchitis Treatment Market Overview
10.3. North America Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Country
10.4. North America Bronchitis Treatment Market Forecast, by Country
10.4.1. U.S.
10.4.2. Canada
10.5. North America Bronchitis Treatment Market Value Share Analysis, by Type
10.6. North America Bronchitis Treatment Market Forecast, by Type
10.6.1. Acute Bronchitis
10.6.2. Chronic Bronchitis
10.7. North America Bronchitis Treatment Market Value Share Analysis, by Drug Class
10.8. North America Bronchitis Treatment Market Forecast, by Drug Class
10.8.1. Antibiotics
10.8.2. Anti-inflammatory Drugs
10.8.3. Bronchodilators
10.8.4. Mucolytics
10.9. North America Bronchitis Treatment Market Value Share Analysis, by Distribution Channel
10.10. North America Bronchitis Treatment Market Forecast, by Distribution Channel
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacies
10.10.3. Online Pharmacies
10.11. North America Bronchitis Treatment Market Attractiveness Analysis
11. Europe Bronchitis Treatment Market Analysis
11.1. Key Findings
11.2. Europe Bronchitis Treatment Market Overview
11.3. Europe Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.4. Europe Bronchitis Treatment Market Forecast, by Country/Sub-region
11.4.1. Germany
11.4.2. U.K.
11.4.3. France
11.4.4. Italy
11.4.5. Spain
11.4.6. Rest of Europe
11.5. Europe Bronchitis Treatment Market Value Share Analysis, by Type
11.6. Europe Bronchitis Treatment Market Forecast, by Type
11.6.1. Acute Bronchitis
11.6.2. Chronic Bronchitis
11.7. Europe Bronchitis Treatment Market Value Share Analysis, by Drug Class
11.8. Europe Bronchitis Treatment Market Forecast, by Drug Class
11.8.1. Antibiotics
11.8.2. Anti-inflammatory Drugs
11.8.3. Bronchodilators
11.8.4. Mucolytics
11.9. Europe Bronchitis Treatment Market Value Share Analysis, by Distribution Channel
11.10. Europe Bronchitis Treatment Market Forecast, by Distribution Channel
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Online Pharmacies
11.11. Europe Bronchitis Treatment Market Attractiveness Analysis
12. Asia Pacific Bronchitis Treatment Market Analysis
12.1. Key Findings
12.2. Asia Pacific Bronchitis Treatment Market Overview
12.3. Asia Pacific Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.4. Asia Pacific Bronchitis Treatment Market Forecast, by Country/Sub-region
12.4.1. China
12.4.2. India
12.4.3. Japan
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Type
12.6. Asia Pacific Bronchitis Treatment Market Forecast, by Type
12.6.1. Acute Bronchitis
12.6.2. Chronic Bronchitis
12.7. Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Drug Class
12.8. Asia Pacific Bronchitis Treatment Market Forecast, by Drug Class
12.8.1. Antibiotics
12.8.2. Anti-inflammatory Drugs
12.8.3. Bronchodilators
12.8.4. Mucolytics
12.9. Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Distribution Channel
12.10. Asia Pacific Bronchitis Treatment Market Forecast, by Distribution Channel
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Pharmacies
12.11. Asia Pacific Bronchitis Treatment Market Attractiveness Analysis
13. Latin America Bronchitis Treatment Market Analysis
13.1. Key Findings
13.2. Latin America Bronchitis Treatment Market Overview
13.3. Latin America Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.4. Latin America Bronchitis Treatment Market Forecast, by Country/Sub-region
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Bronchitis Treatment Market Value Share Analysis, by Type
13.6. Latin America Bronchitis Treatment Market Forecast, by Type
13.6.1. Acute Bronchitis
13.6.2. Chronic Bronchitis
13.7. Latin America Bronchitis Treatment Market Value Share Analysis, by Drug Class
13.8. Latin America Bronchitis Treatment Market Forecast, by Drug Class
13.8.1. Antibiotics
13.8.2. Anti-inflammatory Drugs
13.8.3. Bronchodilators
13.8.4. Mucolytics
13.9. Latin America Bronchitis Treatment Market Value Share Analysis, by Distribution Channel
13.10. Latin America Bronchitis Treatment Market Forecast, by Distribution Channel
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Pharmacies
13.11. Latin America Bronchitis Treatment Market Attractiveness Analysis
14. Middle East & Africa Bronchitis Treatment Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Bronchitis Treatment Market Overview
14.3. Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Country/Sub-region
14.4. Middle East & Africa Bronchitis Treatment Market Forecast, by Country/Sub-region
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. Rest of Middle East and Africa
14.5. Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Type
14.6. Middle East & Africa Bronchitis Treatment Market Forecast, by Type
14.6.1. Acute Bronchitis
14.6.2. Chronic Bronchitis
14.7. Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Drug Class
14.8. Middle East & Africa Bronchitis Treatment Market Forecast, by Drug Class
14.8.1. Antibiotics
14.8.2. Anti-inflammatory Drugs
14.8.3. Bronchodilators
14.8.4. Mucolytics
14.9. Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Distribution Channel
14.10. Middle East & Africa Bronchitis Treatment Market Forecast, by Distribution Channel
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Pharmacies
14.11. Middle East & Africa Bronchitis Treatment Market Attractiveness Analysis
15. Competition Landscape
15.1. Bronchitis Treatment Market Share Analysis, by Company, 2017
15.2. Competition Matrix
15.3. Company Profiles
15.3.1. AstraZeneca
15.3.1.1. Company Details
15.3.1.2. Business Overview
15.3.1.3. Financial Overview
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Boehringer Ingelheim International GmbH
15.3.2.1. Company Details
15.3.2.2. Business Overview
15.3.2.3. Financial Overview
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. GlaxoSmithKline plc
15.3.3.1. Company Details
15.3.3.2. Business Overview
15.3.3.3. Financial Overview
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Novartis AG
15.3.4.1. Company Details
15.3.4.2. Business Overview
15.3.4.3. Financial Overview
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Melinta Therapeutics
15.3.5.1. Company Details
15.3.5.2. Business Overview
15.3.5.3. Financial Overview
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Dr Reddy's Laboratories Ltd
15.3.6.1. Company Details
15.3.6.2. Business Overview
15.3.6.3. Financial Overview
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Sanofi S.A.
15.3.7.1. Company Details
15.3.7.2. Business Overview
15.3.7.3. Financial Overview
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
List of Tables
Table 01: Pipeline Analysis
Table 02: Global Bronchitis Treatment Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 03: Global Bronchitis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 04: Global Bronchitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 05: Global Bronchitis Treatment Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 06: North America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 07: North America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 08: North America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 09: North America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 10: Europe Bronchitis Treatment Market Value (US$ Mn) Forecast, by Country/Region 2016–2026
Table 11: Europe Bronchitis Treatment Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 12: Europe Bronchitis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 13: Europe Bronchitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 14: Asia Pacific Bronchitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region 2016–2026
Table 15: Asia Pacific Bronchitis Treatment Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 16: Asia Pacific Bronchitis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 17: Asia Pacific Bronchitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 18: Latin America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 19: Latin America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 20: Latin America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 21: Latin America Bronchitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 22: Middle East & Africa Bronchitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region,
Table 23: Middle East & Africa Bronchitis Treatment Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 24: Middle East & Africa Bronchitis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 25: Middle East & Africa Bronchitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
List of Figures
Figure 01: Global Bronchitis Treatment Market Value (US$ Mn) and Distribution, by Region, 2018 and 2026
Figure 02: Global Bronchitis Treatment Market Revenue Projection (US$ Mn), 2016–2026
Figure 03: Global Bronchitis Treatment Market Value Share, by Type, 2017
Figure 04: Global Bronchitis Treatment Market Value Share, by Drug Class, 2017
Figure 05: Global Bronchitis Treatment Market Value Share, by Region, 2017
Figure 06: Global Bronchitis Treatment Market Value Share, by Distribution Channel, 2017
Figure 07: Global Bronchitis Treatment Market Value Share Analysis by Type, 2017 and 2026
Figure 08: Global Bronchitis Treatment Market Attractiveness, by Type, 2018–2026
Figure 09: Global Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Chronic Bronchitis, 2016–2026
Figure 10: Global Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Acute Bronchitis, 2016–2026
Figure 11: Global Bronchitis Treatment Market Value Share Analysis by Drug Class, 2017 and 2026
Figure 12: Global Bronchitis Treatment Market Attractiveness, by Drug Class, 2018–2026
Figure 13: Global Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Antibiotics, 2016–2026
Figure 14: Global Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Anti-Inflammatory Drugs, 2016–2026
Figure 15: Global Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Bronchodilators, 2016–2026
Figure 16: Global Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Mucolytics, 2016–2026
Figure 17: Global Bronchitis Treatment Market Value Share, by Distribution Channel, 2017 and 2026
Figure 18: Global Bronchitis Treatment Market Attractiveness, by Distribution Channel, 2018–2026
Figure 19: Global Bronchitis Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2016–2026
Figure 20: Global Bronchitis Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2016–2026
Figure 21: Global Bronchitis Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2016-2026
Figure 22: Global Bronchitis Treatment Market Value Share, by Region, 2016 and 2025
Figure 23: Global Bronchitis Treatment Market Attractiveness, by Region, 2018–2026
Figure 24: North America Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
Figure 25: North America Bronchitis Treatment Market Value Share Analysis, by Country, 2017 and 2026
Figure 26: North America Bronchitis Treatment Market Attractiveness Analysis, by Country, 2018-2026
Figure 27: North America Bronchitis Treatment Market Value Share Analysis, by Type, 2017 and 2026
Figure 28: North America Bronchitis Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 29: North America Bronchitis Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 30: North America Bronchitis Treatment Market Attractiveness Analysis, by Type, 2018–2026
Figure 31: North America Bronchitis Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 32: North America Bronchitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 33: Europe Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
Figure 34: Europe Bronchitis Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 35: Europe Bronchitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
Figure 36: Europe Bronchitis Treatment Market Value Share Analysis, by Type, 2017 and 2026
Figure 37: Europe Bronchitis Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 38: Europe Bronchitis Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 39: Europe Bronchitis Treatment Market Attractiveness Analysis, by Type, 2018–2026
Figure 40: Europe Bronchitis Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 41: Europe Bronchitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 42: Asia Pacific Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 43: Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 44: Asia Pacific Bronchitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
Figure 45: Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Type, 2017 and 2026
Figure 46: Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 47: Asia Pacific Bronchitis Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 48: Asia Pacific Bronchitis Treatment Market Attractiveness Analysis, by Type, 2018–2026
Figure 49: Asia Pacific Bronchitis Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 50: Asia Pacific Bronchitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 51: Latin America Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 52: Latin America Bronchitis Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 53: Latin America Bronchitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
Figure 54: Latin America Bronchitis Treatment Market Value Share Analysis, by Type, 2017 and 2026
Figure 55: Latin America Bronchitis Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 56: Latin America Bronchitis Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 57: Latin America Bronchitis Treatment Market Attractiveness Analysis, by Type, 2018–2026
Figure 58: Latin America Bronchitis Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 59: Latin America Bronchitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 60: Middle East & Africa Bronchitis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 61: Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 62: Middle East & Africa Bronchitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 63: Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Type, 2017 and 2026
Figure 64: Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 65: Middle East & Africa Bronchitis Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 66: Middle East & Africa Bronchitis Treatment Market Attractiveness Analysis, by Type, 2018–2026
Figure 67: Middle East & Africa Bronchitis Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 68: Middle East & Africa Bronchitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 69: Global Bronchitis Treatment Market Share, by Company, 2017
Figure 70: AstraZeneca Breakdown of Net Sales (%), by Region, 2017
Figure 71: AstraZeneca R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 72: AstraZeneca Breakdown of Net Sales (%), by Product Segment, 2017
Figure 73: Boehringer Ingelheim International GmbH, Human Pharmaceuticals Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 74: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Region, 2017
Figure 75: Boehringer Ingelheim International GmbH R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 76: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Business Segment, 2017
Figure 77: GlaxoSmithKline plc Respiratory Business Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 78: GlaxoSmithKline plc Breakdown of Net Sales (%), by Region, 2017
Figure 80: GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2017
Figure 81: Novartis AG COPD Portfolio Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 82: Novartis AG Breakdown of Net Sales (%), by Country, 2017
Figure 83: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 84: Novartis AG Breakdown of Net Sales (%), by Business Segment, 2017
Figure 85: Melinta Therapeutics Respiratory Medicine Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 86: Melinta Therapeutics Breakdown of Net Sales (%), by Region, 2017
Figure 87: Melinta Therapeutics R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 88: Melinta Therapeutics Breakdown of Net Sales (%), by Business Segment, 2017
Figure 89: Dr Reddy's Laboratories Ltd., Ltd Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 90: Dr Reddy's Laboratories Ltd., Breakdown of Net Sales (%), by Region, 2017
Figure 91: Dr Reddy's Laboratories Ltd., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 92: Dr Reddy's Laboratories Ltd., Breakdown of Net Sales (%), by Product Segment, 2017
Figure 93: Sanofi S.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 94: Sanofi S.A. Breakdown of Net Sales (%), by Region, 2017
Figure 95: Sanofi S.A. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 96: Sanofi S.A. Breakdown of Net Sales (%), by Therapeutics Area, 2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Bronchitis Treatment Market
